solid tumors with pre specified mdm2 amplification levels epidemiology forecast
DelveInsight's "Solid Tumors With Pre-specified MDM2 Amplification Levels - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Solid Tumors With Pre-specified MDM2 Amplification Levels epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Geographies Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2021-2034
Solid Tumors With Pre-specified MDM2 Amplification Levels Understanding
The DelveInsight Solid Tumors With Pre-specified MDM2 Amplification Levels epidemiology report gives a thorough understanding of the Solid Tumors With Pre-specified MDM2 Amplification Levels by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Solid Tumors With Pre-specified MDM2 Amplification Levels in the US, Europe, and Japan. The report covers the detailed information of the Solid Tumors With Pre-specified MDM2 Amplification Levels epidemiology scenario in seven major countries (US, EU5, and Japan).
Recent Development
- In Oct 2026, Beactica Therapeutics announced the selection of BEA-28 as a formal preclinical candidate, establishing it as a first-in-class targeted TEAD degrader for biomarker-selected cancers. BEA-28 is designed to inhibit the Hippo signaling pathway by selectively breaking down TEAD transcription factors, which drive tumor growth in various oncology indications. This milestone advances Beactica's pipeline of precision oncology therapies, offering a novel mechanism to tackle drug-resistant solid tumors and address critical unmet medical needs.
- In Oct 2026, Alpha-9 Oncology announced that clinical data evaluating its gastrin-releasing peptide receptor (GRPR)-targeting radiopharmaceutical compound, ⁶⁸Ga-A9-6217, will be presented at the European Association of Nuclear Medicine (EANM) 2026 Annual Congress. The presentation highlights Phase 1 study data investigating the safety, biodistribution, and imaging dosimetry of ⁶⁸Ga-A9-6217 across advanced solid tumors, validating its utility as a diagnostic radiotracer to select patients for targeted radioligand therapies.
- In Sep 2026, Biohaven announced that clinical data for BHV-1530—a novel FGFR3-directed antibody-drug conjugate (ADC) incorporating a proprietary Topoisomerase I (TOPOiX) payload—was selected for an oral presentation at the EORTC-NCI-AACR Symposium 2026. The findings detail initial clinical safety, tolerability, and anti-tumor activity in advanced solid tumors.
- In Sep 2026, Link Cell Therapies initiated clinical dosing in a Phase 1 trial evaluating its novel logic-gated CAR-T therapy for solid tumors. Concurrently, the company expanded its executive team and upsized its Series A financing to $90 million to support pipeline expansion and clinical execution.
- In Sep 2026, Nutshell Therapeutics received U.S. FDA Investigational New Drug (IND) clearance for NTS231, marking the entrance of the second-ever NRF2 degrader into clinical trials. NTS231 utilizes targeted protein degradation to downregulate NRF2, an overexpressed oncogenic driver involved in treatment resistance and tumor survival across several solid cancers.
- In Sep 2026, Amberstone Biosciences signed a collaboration and licensing agreement with Shanghai Henlius Biotech to co-develop conditionally activated T-cell engagers (TCEs) targeting solid tumors. The partnership leverages Amberstone's proprietary T-MATE™ platform, which designs pH-gated antibody therapies that selectively activate inside the acidic microenvironment of solid tumors while staying inactive in healthy tissue to minimize systemic toxicity. Henlius gains access to novel candidates to complement its oncology portfolio, while Amberstone accelerates the development of its preclinical T-cell engager pipeline.
- In Sep 2026, Akeso announced that China's NMPA granted Phase I clinical trial clearance for AK158D1, a first-in-class EGFR/TROP2 bispecific antibody-drug conjugate (ADC). Targeted for advanced solid tumors, this clearance marks Akeso’s fourth ADC candidate to reach the clinical stage, highlighting the company's rapid expansion in next-generation targeted oncology therapeutics.
- In August 2026, Senhwa Biosciences completed patient enrollment for its Phase 1b expansion trial evaluating CX-5461 in solid tumors. The drug targets G-quadruplex structures to induce DNA damage in cancer cells. With enrollment finalized, Senhwa announced that the clinical study report (CSR) is expected in Q1 2027, paving the way for future efficacy assessments and potential combination therapies.
- In Sep 2026, 1CBio and Lee's Pharmaceutical entered an exclusive licensing agreement worth up to $150M to develop and commercialize OC-3, a highly selective PARP1 inhibitor, in Greater China and Southeast Asia. OC-3 is designed to target PARP1 without inhibiting PARP2, potentially reducing hematological toxicities common with first-generation therapies. 1CBio retains rights outside Asia and continues its Phase 1 trials for solid tumors.
- In Sep 2026, Marengo Therapeutics completed enrollment in the Phase 1/2 START-001 monotherapy cohorts evaluating invikafusp alfa. Designed to selectively activate Vβ12.1 T cells, the precision T-cell caller showed encouraging safety and anti-tumor activity in advanced solid tumors. Alongside the milestone, Marengo strengthened its executive leadership to guide the asset into late-stage development.
- In Sep 2026, Acepodia received U.S. FDA clearance for its Investigational New Drug application for ACE723, a novel antibody-drug conjugate (ADC) featuring a dual-payload mechanism. Utilizing Acepodia's antibody cell conjugation platform, ACE723 delivers two distinct cytotoxic agents directly to tumor cells to overcome single-agent therapeutic resistance. The clearance allows Acepodia to initiate Phase 1 clinical testing evaluating safety, pharmacokinetics, and initial anti-tumor efficacy in patients with advanced solid tumors.
- In Sep 2026, HanchorBio achieved a clinical milestone for HCB101 after the US FDA approved an individual patient expansion (IPE) protocol. The decision allows a Phase 1 patient suffering from advanced solid tumors to continue receiving the multi-targeted antibody-like bi-specific molecule after demonstrating sustained, meaningful clinical benefit and manageable safety.
Solid Tumors With Pre-specified MDM2 Amplification Levels Epidemiology Perspective by DelveInsight
The Solid Tumors With Pre-specified MDM2 Amplification Levels epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Solid Tumors With Pre-specified MDM2 Amplification Levels epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Solid Tumors With Pre-specified MDM2 Amplification Levels epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2021 to 2034. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.
Solid Tumors With Pre-specified MDM2 Amplification Levels Detailed Epidemiology Segmentation
The Solid Tumors With Pre-specified MDM2 Amplification Levels epidemiology covered in the report provides historical as well as forecasted Solid Tumors With Pre-specified MDM2 Amplification Levels epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2021 to 2034.
The DelveInsight Solid Tumors With Pre-specified MDM2 Amplification Levels report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.
Scope of the Report
- The Solid Tumors With Pre-specified MDM2 Amplification Levels report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
- The Solid Tumors With Pre-specified MDM2 Amplification Levels Epidemiology Report and Model provide an overview of the global trends of Solid Tumors With Pre-specified MDM2 Amplification Levels in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
- The report provides insight into the historical and forecasted patient pool of Solid Tumors With Pre-specified MDM2 Amplification Levels in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
- The report helps recognize the growth opportunities in the 7MM for the patient population
- The report assesses the disease risk and burden and highlights the unmet needs of Solid Tumors With Pre-specified MDM2 Amplification Levels
- The report provides the segmentation of the Solid Tumors With Pre-specified MDM2 Amplification Levels epidemiology
Report Highlights
- 10-year forecast of Solid Tumors With Pre-specified MDM2 Amplification Levels epidemiology
- 7MM Coverage
- Prevalent and Diagnosed Cases of Solid Tumors With Pre-specified MDM2 Amplification Levels
- Cases of Solid Tumors With Pre-specified MDM2 Amplification Levels by Mutation Types
- Solid Tumors With Pre-specified MDM2 Amplification Levels Cases associated with Clinical Manifestations
KOL views
We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Solid Tumors With Pre-specified MDM2 Amplification Levels?
- What are the key findings pertaining to the Solid Tumors With Pre-specified MDM2 Amplification Levels epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2025-2034)?
- What would be the total number of patients of Solid Tumors With Pre-specified MDM2 Amplification Levels across the 7MM during the forecast period (2025-2034)?
- Among the EU5 countries, which country will have the highest number of patients during the forecast period (2025-2034)?
- At what CAGR the patient population is expected to grow in 7MM during the forecast period (2025-2034)?
- What is the disease risk, burden and unmet needs of Solid Tumors With Pre-specified MDM2 Amplification Levels?
- What are the currently available treatments of Solid Tumors With Pre-specified MDM2 Amplification Levels?
Reasons to buy
The Solid Tumors With Pre-specified MDM2 Amplification Levels Epidemiology report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the global Solid Tumors With Pre-specified MDM2 Amplification Levels market
- Quantify patient populations in the global Solid Tumors With Pre-specified MDM2 Amplification Levels market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Solid Tumors With Pre-specified MDM2 Amplification Levels therapeutics in each of the markets covered
- Understand the magnitude of Solid Tumors With Pre-specified MDM2 Amplification Levels population by its epidemiology
- The Solid Tumors With Pre-specified MDM2 Amplification Levels Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 10-year forecast period using reputable sources
Key Assessments
- Patient Segmentation
- Disease Risk & Burden
- Risk of disease by the segmentation
- Factors driving growth in a specific patient population


